Randomized and open clinical trials were conducted to evaluate the efficacy and safety of scientific exercise combined with gynostemma pentaphyllum granules in the treatment of dyslipidemia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049411

Enrollment

Unknown

Registered

2021-08-02

Start date

2021-11-22

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dyslipidemia

Interventions

Control group:exercise prescription for treatment

Experimental group:Gynostemma pentaphyllum total glycoside granules + exercise prescription for treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years, gender is not limited; after pre-assessment, they can receive exercise prescription therapy; 2. Clearly understand and voluntarily participate in the research, and sign the informed consent; 3. Patients who meet the diagnosis of dyslipidemia and do not take statins. According to the "Guidelines for the Prevention and Treatment of Dyslipidemia in Adults in China", the following standards are met: non-HDL-C>=4.2mmol/L (160mg/dl).

Exclusion criteria

Exclusion criteria: 1. Patients with hepatitis, schistosomiasis liver disease or liver cirrhosis caused by viral hepatitis, drug poisoning, immune diseases and other factors; 2. Patients with serious primary diseases of heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract; 3. Subjects with poor compliance with the research protocol or those who have recently or are participating in other clinical trials; 4. Women who are breastfeeding, pregnant or planning to become pregnant; 5. Those who have participated in other clinical trials of new drugs within 30 days before screening; 6. Contraindications to moderate physical exercise, inability to walk independently; 7. Suffer from a cognitive or psychiatric disorder that limits the full understanding of the research; 8. Other reasons that the investigator considers unsuitable to participate in the trial; 9. Those with allergic constitution, those who are allergic to the ingredients contained in Gynostemma Gynostemma granules.

Design outcomes

Primary

Measure	Time frame
Changes in blood lipid index non-high-density lipoprotein cholesterol compared with baseline after 3 months of treatment;	—

Secondary

Measure	Time frame
Cardiovascular function index;The biochemical indicators;Body mass index;change in Body mass index;waist hip rate;	—

Countries

China

Contacts

Public ContactJing Zhiqiang

China Pharmaceutical University

Jingzq@cpu.edu.cn+86 13739197849

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026